DOTFE

DOTFE, also known as 4--2,5-dimethoxyamphetamine, is a drug of the phenethylamine, amphetamine, and DOx families. It is a close analogue of known psychedelics like the DOx psychedelic DOTFM and the 2C psychedelics 2C-TFE and 2C-TFM. The drug was predicted to bind to the serotonin 5-HT_2A receptor, with a predicted affinity of 50nM. It was inactive in humans at doses of up to 3mg, but higher doses were not assessed. DOTFE is expected to be a potent psychedelic at active doses. It was first described in the scientific literature by at least 1999. DOTFE was evaluated in humans by Daniel Trachsel, with these reports published in 2012 and 2013.